by Lupus Foundation, Ohio | Jan 11, 2026 | Lupus Foundation of America, News & Events
AstraZeneca reported positive results from a Phase III TULIP-SC clinical trial, showing a statistically significant and clinically meaningful reduction in disease activity with the subcutaneous (SC), self-administration of Saphnelo (anifrolumab) in adults with...
by Lupus Foundation, Ohio | Jan 9, 2026 | Lupus Foundation of America, News & Events
Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug therapy, nipocalimab, met its primary endpoint and multiple key secondary and exploratory endpoints in adults with systemic lupus...
by | Jan 5, 2026 | Lupus Foundation of America
For people living with lupus, pain can be one of the most persistent and difficult symptoms to manage. Whether it’s joint discomfort, muscle aches or nerve-related pain, lupus symptoms can make daily activities feel overwhelming. But the good news is that a...
by | Dec 18, 2025 | Lupus Foundation of America, News & Events
A new study finds that experiences of discrimination are associated with worse patient-reported lupus-related symptoms and depressive symptoms among people with systemic lupus erythematosus (SLE). Patient-reported disease activity such as pain, fatigue and depression...
by | Dec 17, 2025 | Lupus Foundation of America
“I’m waiting for you to give me a problem. Don’t worry, we got this.”These simple words spoken to Latasha Green by her now husband when they started dating meant that a family might one day be possible. Diagnosed at 24, Latasha knew that her...
by | Dec 16, 2025 | Lupus Foundation of America, News & Events
In a new study, researchers have discovered a connection between inflammation in the areas of interstitial fibrosis and tubular atrophy (IFTA), a common pattern of kidney damage often seen in kidney disease, and renal outcomes. The researchers found that inflammation...
